These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 23340795)

  • 1. Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple‑negative breast cancer cells.
    Lee J; Gollahon L
    Int J Oncol; 2013 Mar; 42(3):839-47. PubMed ID: 23340795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
    Spänkuch B; Heim S; Kurunci-Csacsko E; Lindenau C; Yuan J; Kaufmann M; Strebhardt K
    Cancer Res; 2006 Jun; 66(11):5836-46. PubMed ID: 16740723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nek2 as a novel molecular target for the treatment of breast carcinoma.
    Tsunoda N; Kokuryo T; Oda K; Senga T; Yokoyama Y; Nagino M; Nimura Y; Hamaguchi M
    Cancer Sci; 2009 Jan; 100(1):111-6. PubMed ID: 19038001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LIN9 and NEK2 Are Core Regulators of Mitotic Fidelity That Can Be Therapeutically Targeted to Overcome Taxane Resistance.
    Roberts MS; Sahni JM; Schrock MS; Piemonte KM; Weber-Bonk KL; Seachrist DD; Avril S; Anstine LJ; Singh S; Sizemore ST; Varadan V; Summers MK; Keri RA
    Cancer Res; 2020 Apr; 80(8):1693-1706. PubMed ID: 32054769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
    Tanabe K; Kim R; Inoue H; Emi M; Uchida Y; Toge T
    Int J Oncol; 2003 Apr; 22(4):875-81. PubMed ID: 12632082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitotic perturbations induced by Nek2 overexpression require interaction with TRF1 in breast cancer cells.
    Lee J; Gollahon L
    Cell Cycle; 2013 Dec; 12(23):3599-614. PubMed ID: 24091727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.
    Hu K; Law JH; Fotovati A; Dunn SE
    Breast Cancer Res; 2012 Feb; 14(1):R22. PubMed ID: 22309939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel combination treatment for colorectal cancer using Nek2 siRNA and cisplatin.
    Suzuki K; Kokuryo T; Senga T; Yokoyama Y; Nagino M; Hamaguchi M
    Cancer Sci; 2010 May; 101(5):1163-9. PubMed ID: 20345485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing chemosensitivity of wild-type and drug-resistant MDA-MB-231 triple-negative breast cancer cell line to doxorubicin by silencing of STAT 3, Notch-1, and β-catenin genes.
    Alkaraki A; Alshaer W; Wehaibi S; Gharaibeh L; Abuarqoub D; Alqudah DA; Al-Azzawi H; Zureigat H; Souleiman M; Awidi A
    Breast Cancer; 2020 Sep; 27(5):989-998. PubMed ID: 32328816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer.
    Bhola NE; Balko JM; Dugger TC; Kuba MG; Sánchez V; Sanders M; Stanford J; Cook RS; Arteaga CL
    J Clin Invest; 2013 Mar; 123(3):1348-58. PubMed ID: 23391723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.
    Spänkuch B; Kurunci-Csacsko E; Kaufmann M; Strebhardt K
    Oncogene; 2007 Aug; 26(39):5793-807. PubMed ID: 17369857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy.
    Falamarzian A; Aliabadi HM; Molavi O; Seubert JM; Lai R; Uludağ H; Lavasanifar A
    J Biomed Mater Res A; 2014 Sep; 102(9):3216-28. PubMed ID: 24167124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticlusterin treatment of breast cancer cells increases the sensitivities of chemotherapy and tamoxifen and counteracts the inhibitory action of dexamethasone on chemotherapy-induced cytotoxicity.
    Redondo M; Téllez T; Roldan MJ; Serrano A; García-Aranda M; Gleave ME; Hortas ML; Morell M
    Breast Cancer Res; 2007; 9(6):R86. PubMed ID: 18078515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.
    Anbalagan M; Ali A; Jones RK; Marsden CG; Sheng M; Carrier L; Bu Y; Hangauer D; Rowan BG
    Mol Cancer Ther; 2012 Sep; 11(9):1936-47. PubMed ID: 22784709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Over-expression of ERp29 attenuates doxorubicin-induced cell apoptosis through up-regulation of Hsp27 in breast cancer cells.
    Zhang D; Putti TC
    Exp Cell Res; 2010 Dec; 316(20):3522-31. PubMed ID: 20833165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide.
    Simões-Wüst AP; Schürpf T; Hall J; Stahel RA; Zangemeister-Wittke U
    Breast Cancer Res Treat; 2002 Nov; 76(2):157-66. PubMed ID: 12452453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity.
    Menendez JA; Vellon L; Colomer R; Lupu R
    Int J Cancer; 2005 May; 115(1):19-35. PubMed ID: 15657900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silencing of Nek2 suppresses the proliferation, migration and invasion and induces apoptosis of breast cancer cells by regulating ERK/MAPK signaling.
    Xing Z; Zhang M; Wang X; Liu J; Liu G; Feng K; Wang X
    J Mol Histol; 2021 Aug; 52(4):809-821. PubMed ID: 34009515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer.
    Gasca J; Flores ML; Giráldez S; Ruiz-Borrego M; Tortolero M; Romero F; Japón MA; Sáez C
    Oncotarget; 2016 Aug; 7(33):52751-52765. PubMed ID: 27409838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nek2 siRNA therapy using a portal venous port-catheter system for liver metastasis in pancreatic cancer.
    Kokuryo T; Hibino S; Suzuki K; Watanabe K; Yokoyama Y; Nagino M; Senga T; Hamaguchi M
    Cancer Sci; 2016 Sep; 107(9):1315-20. PubMed ID: 27316377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.